GlassScriptPhysician profile
Bradley D Gonik
NPI 1952862765
$1,756.87
in general payments reported to CMS, 2019-2025
24 companies · $637 in 2025
The $637 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $363 · 2024: $757 · 2025: $637.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $300.45 | 2023-2025 | |
| Novo Nordisk INC | $253.44 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Eisai INC. | $202.95 | 2024-2025 | |
| Glaxosmithkline, LLC. | $159.27 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $135.03 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $129.00 | 2025 | |
| Pharmacosmos Therapeutics INC. | $106.93 | 2024 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $59.49 | 2023-2025 | Airsupra, Fasenra |
| Lilly USA, LLC | $49.56 | 2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $46.84 | 2023-2024 | Proclaim |
| Boston Scientific Corporation | $42.63 | 2025 | Watchman Access System, Watchman Flx |
| Mylan Specialty L.P. | $34.53 | 2023 | Yupelri |
| Dexcom, INC. | $32.86 | 2023-2025 | Dexcom G6 Transmitter |
| Cleerly, INC. | $27.04 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.52 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $22.00 | 2025 | Gemtesa |
| Astellas Pharma US INC | $20.00 | 2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $19.94 | 2023 | Gvoke Hypopen |
| Exact Sciences Corporation | $17.89 | 2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $14.59 | 2025 | Capvaxive, Gardasil 9 |
| Baxter Healthcare | $14.55 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Amgen INC. | $14.50 | 2025 | Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Gonik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.